February 2007
Gut;Feb2007 Supplement 1, Vol. 56, p37
Academic Journal
The article focuses on the prevalence of obesity in Great Britain and its impact on the delivery of gastrointestinal (GI) services in the country.


Related Articles

  • Duodenum Exclusion Alone Is Sufficient to Reduce Fasting Blood Glucose in Non-Obese Diabetic Goto-Kakizaki Rats. Ke, Jun; Wang, Yu // Obesity Surgery;Mar2014, Vol. 24 Issue 3, p433 

    A letter to the editor is presented in response to several articles on topics including systematic review and meta-analysis of bariatric surgery, effect of laparoscopic gastroenterostomy in type 2 diabetes mellitus and diabetes control after gastrointestinal bypass surgery.

  • Ten top tips for commissioning GI services. O'Malley, John // Pulse;7/18/2012, Vol. 72 Issue 25, p35 

    The article offers tips on how to commission services for liver and gastrointestinal (GI) disorders. It mentions the importance of the early detection of alcohol problems. It says that commissioners should also screen viral hepatitis and obesity. It adds that education opportunities and...

  • Gastrointestinal and Nutritional Complications After Bariatric Surgery. Decker, G. Anton; Swain, James M.; Crowell, Michael D.; Scolapio, James S. // American Journal of Gastroenterology;Nov2007, Vol. 102 Issue 11, p2571 

    The prevalence of obesity has increased to epidemic proportions, making obesity and its comorbid conditions a major public health concern. Bariatric surgery is the most effective treatment, but it carries substantial morbidity. The subsequent gastrointestinal and nutritional complications are...

  • Synergy Pharmaceuticals Advances Its Preclinical Research Program For The Use Of Guanylate Cyclase C Agonists To Lower Cholesterol.  // Biomedical Market Newsletter;5/17/2011, p355 

    The article focuses on the completion of Synergy Pharmaceuticals Inc. on its preclinical in vitro research for the inhibition of bile acid uptake by guanylyl cyclase C (GC-C) agonists. It states that the GC-C is a non-systemic drugs developed to treat constipation-predominant-irritable bowel...

  • INTRODUCTION.  // Gut;Feb2007 Supplement 1, Vol. 56, p19 

    An introduction is presented on various topics related to gastrointestinal disorders including the diagnosis, treatment and management of the disease.

  • Generic omeprazole approved.  // WHO Drug Information;2002, Vol. 16 Issue 3, p229 

    Reports on the U.S. Food and Drug Administration's approval of 10 and 20-milligram omeprazole delayed-release capsules for the treatment of certain gastro-intestinal conditions. Similarity of the generic drug to its branded counterpart.

  • Taming the beast in the belly. Graham, Lamar // GQ: Gentlemen's Quarterly;Jun93, Vol. 63 Issue 6, p222 

    Gives advice on how to avoid heartburn. Sleeping on the left side; Raising the head four to six inches with pillows.

  • Easing irritable bowel syndrome. Lipman, Marvin M. // Consumer Reports on Health;Aug92, Vol. 4 Issue 8, p62 

    Presents an article which discusses irritable bowel syndrome, alternating bouts of diarrhea and constipation, abdominal pains before bowel movements, bloated feeling, and embarrassing gas. Diagnosing the syndrome; Self-help for the syndrome and beyond.

  • Robotics being designed to treat common gastrointestinal conditions.  // Gastrointestinal Nursing;Oct2012, Vol. 10 Issue 8, p8 

    The article reports that a Missouri-based company, EndoStim, has received approval to sell its robotic implantable device for treating severe gastrooesophageal reflux disease through electrical stimulation.


Read the Article


Sign out of this library

Other Topics